|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0010802,
umls-concept:C0023473,
umls-concept:C0030705,
umls-concept:C0035696,
umls-concept:C0040223,
umls-concept:C0205197,
umls-concept:C0441889,
umls-concept:C0681842,
umls-concept:C0871261,
umls-concept:C0935989,
umls-concept:C1552913,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1955905,
umls-concept:C1977882,
umls-concept:C2248809,
umls-concept:C2911692,
umls-concept:C2926735
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2006-5-23
|
|
pubmed:abstractText |
Although most patients with chronic myeloid leukemia (CML) treated with imatinib mesylate achieve a complete cytogenetic response (CCR), some patients will relapse. To determine the potential of real-time quantitative BCR-ABL reverse transcriptase-polymerase chain reaction (RT-PCR) to predict the duration of continued CCR, we monitored 85 patients treated with imatinib mesylate who achieved a CCR. With a median follow-up of 13 months after CCR (29 months after imatinib mesylate; median 6 RQ-PCR assays), 23 patients (27%) had disease progression (predominantly loss of CCR). Compared with the median baseline level of BCR-ABL mRNA, 42% of patients achieved at least a 2-log molecular response at the time of first reaching CCR. Failure to achieve a 2-log response at the time of CCR was an independent predictive marker of subsequent progression-free survival (hazard ratio = 5.8; 95% CI, 1.7-20; P = .005). After CCR, BCR-ABL mRNA levels progressively declined for at least the next 15 months, and 42 patients (49%) ultimately achieved at least a 3-log reduction in BCR-ABL mRNA. Patients failing to achieve this 3-log response, at any time during therapy, had significantly shorter progression-free survival (hazard ratio = 8.1; 95% CI, 3.1-22; P < .001). The achievement of either a 2-log molecular response at the time of CCR or a 3-log response anytime thereafter is a significant and independent prognostic marker of subsequent progression-free survival.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/16467199-10557058,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16467199-10877287,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16467199-11846609,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16467199-11870241,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16467199-12200666,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16467199-12637609,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16467199-12646934,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16467199-12648069,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16467199-12886230,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16467199-12970765,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16467199-14512312,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16467199-14523461,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16467199-14534335,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16467199-14645009,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16467199-14754606,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16467199-15198956,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16467199-15703781,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16467199-15867244,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16467199-8400243,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16467199-9625174
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0006-4971
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
107
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4250-6
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16467199-Adult,
pubmed-meshheading:16467199-Aged,
pubmed-meshheading:16467199-Cytogenetic Analysis,
pubmed-meshheading:16467199-Disease-Free Survival,
pubmed-meshheading:16467199-Female,
pubmed-meshheading:16467199-Follow-Up Studies,
pubmed-meshheading:16467199-Fusion Proteins, bcr-abl,
pubmed-meshheading:16467199-Humans,
pubmed-meshheading:16467199-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:16467199-Male,
pubmed-meshheading:16467199-Middle Aged,
pubmed-meshheading:16467199-Piperazines,
pubmed-meshheading:16467199-Polymerase Chain Reaction,
pubmed-meshheading:16467199-Prognosis,
pubmed-meshheading:16467199-Pyrimidines,
pubmed-meshheading:16467199-RNA, Messenger,
pubmed-meshheading:16467199-Remission Induction,
pubmed-meshheading:16467199-Time Factors
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.
|
|
pubmed:affiliation |
Department of Pathology, Oregon Health & Science University, Portland, OR 97201, USA. pressr@ohsu.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
